Malignant hyperthermia in a 6-month-old infant

被引:3
作者
Mathur, P. R. [1 ]
Rundla, M. [2 ]
Jain, N. [1 ]
Mathur, V [1 ]
机构
[1] Jawaharlal Nehru Med Coll, Dept Anesthesiol, Ajmer, Rajasthan, India
[2] Fortis Escorts Hosp, Dept Anaesthesiol, Jaipur, Rajasthan, India
关键词
Halothane; malignant hyperthermia; malignant hyperthermia clinical grading scale; succinylcholine;
D O I
10.4103/1658-354X.174915
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Malignant hyperthermia (MH) is a rare hypermetabolic disorder of skeletal muscles that manifests as a life-threatening crisis in susceptible individuals, after exposure to triggering agents, most commonly halothane and succinylcholine. MH presents with multiple nonspecific signs and laboratory findings such as tachycardia, hyperthermia, hypercarbia, acidosis, and muscle rigidity. Caffeine halothane contracture test is not available at most centers in India. Larach et al. have described a clinical grading scale for determining the MH raw score based on clinical findings and biochemical tests. The high degree of suspicion, early recognition and aggressive treatment should commence immediately. It is imperative to avoid triggering agents, such as volatile anesthetics and succinylcholine, and promote the use of total intravenous anesthesia in MH susceptible patients. We report a case of 6-month-old child undergoing laparotomy under general anesthesia, who presented with signs and symptoms of MH, had MbH rank 5 and raw score 36.
引用
收藏
页码:353 / 355
页数:3
相关论文
共 8 条
[1]   CREATINE-KINASE ALTERATIONS AFTER ACUTE MALIGNANT HYPERTHERMIA EPISODES AND COMMON SURGICAL-PROCEDURES [J].
ANTOGNINI, JF .
ANESTHESIA AND ANALGESIA, 1995, 81 (05) :1039-1042
[2]   Simulation-Based Trial of Surgical-Crisis Checklists [J].
Arriaga, Alexander F. ;
Bader, Angela M. ;
Wong, Judith M. ;
Lipsitz, Stuart R. ;
Berry, William R. ;
Ziewacz, John E. ;
Hepner, David L. ;
Boorman, Daniel J. ;
Pozner, Charles N. ;
Smink, Douglas S. ;
Gawande, Atul A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (03) :246-253
[3]   Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group [J].
Glahn, K. P. E. ;
Ellis, F. R. ;
Halsall, P. J. ;
Mueller, C. R. ;
Snoeck, M. M. J. ;
Urwyler, A. ;
Wappler, F. .
BRITISH JOURNAL OF ANAESTHESIA, 2010, 105 (04) :417-420
[4]   Malignant hyperthermia: pharmacology of triggering [J].
Hopkins, P. M. .
BRITISH JOURNAL OF ANAESTHESIA, 2011, 107 (01) :48-56
[5]  
KAUS SJ, 1994, PEDIATR CLIN N AM, V41, P221
[6]   Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America from 1987 to 2006 [J].
Larach, Marilyn Green ;
Gronert, Gerald A. ;
Allen, Gregory C. ;
Brandom, Barbara W. ;
Lehman, Erik B. .
ANESTHESIA AND ANALGESIA, 2010, 110 (02) :498-507
[7]   A CLINICAL GRADING SCALE TO PREDICT MALIGNANT HYPERTHERMIA SUSCEPTIBILITY [J].
LARACH, MG ;
LOCALIO, AR ;
ALLEN, GC ;
DENBOROUGH, MA ;
ELLIS, FR ;
ANAES, FRC ;
GRONERT, GA ;
KAPLAN, RF ;
MULDOON, SM ;
NELSON, TE ;
ORDING, H ;
ROSENBERG, H ;
WAUD, BE ;
WEDEL, DJ .
ANESTHESIOLOGY, 1994, 80 (04) :771-779
[8]  
MELTON AT, 1989, ANESTH ANALG, V69, P437